Published 3-29-2021
FUJIFILM Diosynth Biotechnologies is planning to construct a $2 billion biopharmaceutical production facility in Holly Springs, N.C.
Published 3-1-2021
Vibalogics is creating a 110,000-sf facility for the production of oncolytic viruses, viral vector vaccines, and viral vector gene therapy products in Boxborough, Mass.
Published 2-5-2021
Civica Rx began construction in early 2021 on a $124.5 million pharmaceutical manufacturing center in Petersburg, Va.
Published 1-27-2021
Universal Robots is partnering with Mobile Industrial Robots to create a research and development campus in Odense, Denmark.
Published 1-25-2021
The Massachusetts Center for Advanced Biological Innovation and Manufacturing is planning to create a 40,000-sf facility in Watertown, Mass.
Published 1-4-2021
Thermo Fisher Scientific is expanding its global production capacity for vaccines, medicines, and biologic therapies.
Published 12-21-2020
Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio.
Published 12-16-2020
The life sciences industry has become the great hope in real estate, as we face the most significant public health crisis in a century. While other industries have slowed and suffered as a result of sheltering in place and working from home, science facilities have remained operational and even have thrived in prime markets, as the industry continues to search for medical breakthroughs. The downturn in other industries has left buildings vacant. The life science market, on the other hand, continues to experience some of the lowest vacancy and highest employment rates. For life science organizations in the prime U.S. markets, there simply remains a shortage of available research-capable space. Enter the big pivot to science.
Published 11-30-2020
ApiJect will break ground in December of 2020 on the Gigafactory campus in Durham, N.C.
Published 11-18-2020
Ultragenyx is planning to build a 100,000-sf gene therapy manufacturing facility in Bedford, Mass.
